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Abstract. This work deals with the development of a new 
family of planar chiral phosphoric acids, based on a 
ferrocenophane/paracyclophane scaffold. The synthetic 
approach has been improved by taking advantage of a chiral 
phosphorylating agent to access enantiomerically enriched 
acids via diastereomers separation.  
These phosphoric acids have been used as catalysts for the 
enantioselective H-transfer reduction of -substituted 
quinolines with Hantzsch esters. Optimization of both the 
catalyst and the Hantzsch reductant allowed ee in the range 
82-92% to be attained starting from -arylquinolines.  
Keywords: phosphoric acid; planar chirality; chiral 
phosphorodiamidites; paracyclophanes; organocatalysis.  
 
Introduction 
The use of chiral phosphoric acids in 
organocatalytic processes has experienced an 
exponential growth following to the seminal work of 
Terada[1] and Akiyama[2] on enantioselective Mannich 
type reactions. Among the most classical applications, 
Biginelli, Pictet-Spengler, Friedel-Crafts, ene-type 
and Diels-Alder reactions can be mentioned.[3] 
Moreover, several unprecedented uses have been 
reported recently which include the desymetrization 
of tetrasubstituted biaryls by asymmetric 
bromination,[4], the oxyfluorination of enamides,[5] 
the asymmetric protonation of ketene dithioacetals 
and silyl ketene imines[6] and others.[7] The privileged 
phosphoric acids for these applications are mainly 
issued from chiral BINOL, SPINOL,[8] VANOL and 
VAPOL[9] derivatives, i.e. from C2-symmetric axially 
chiral diols. Surprisingly, planar chirality has not 
been exploited so far for building phosphoric acids, 
although planar chiral structural units are known to 
afford efficient auxiliaries in other fields.[10] In the 
case of phosphoric acids, it can be expected that 
planar chiral scaffolds would create completely 
different asymmetric environments, with respect to 
axially chiral frameworks. They might generate, 
therefore, complementary properties in terms of 
stereoselection and offer new opportunities for 
catalytic applications. This hypothesis led us to 
design phosphoric acids based on planar chiral 
paracyclophane scaffolds as potentially relevant 
targets. Preliminary results from these studies have 
been disclosed in a short communication.[11] In this 
paper we’ll afford (a) more detailed information on 
our design of planar chiral phosphoric acids, (b) an 
improved synthetic approach to optically pure 
compounds, based on the use of a chiral 
phosphorylating agent, (c) more extensive 
investigations on the use of the new acids as 
organocatalysts in the enantioselective H-transfer 
reduction of -substituted quinolines. 
Results and Discussion 
At the start of our studies, our aim was to develop 
a new series of phosphoric acids, based on planar 
chiral paracyclophane scaffolds. As far as we know, 
the literature reports only one compound of this class, 
the Enders’s acid A, in which a phosphoric acid 
function is embedded in the five-atom chain tethering 
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an unsymmetric [2.2]paracyclophane  unit. This 
Brønsted acid catalyst had been evaluated in Mannich 
type reactions affording moderate enantiomeric 
excesses (ee.s up to 38%).[12]  
 
 
Figure 1. Enders planar chiral phosphoric acid (A) and 
targeted structures from this work (B) 
 
Our target structures (B) differ from the Enders acid 
in as far as the O-P-O bridge itself would be a 
constitutive fragment of the C2-symmetric 
paracyclophane framework. In B, planar chirality is 
generated by the two aryl substituents (Ar) on 
opposite edges of the paracyclophane. The only 
previous report on related paracyclophanes and 
ferrocenophanes are due to Nifant’ev[13] and 
Herberhold[14]  who synthesized racemic macrocyclic 
bis-phosphoramidites, and ferrocenic phosphonites 
and phosphates respectively. None of these 
compounds had been prepared in enantiomerically 
enriched form, neither they had been investigated for 
catalytic purposes. 
 
As mentioned in our preliminary 
communication,[11] phosphoric acids of the general 
formula B can be accessed when the tethering chain 
“X” is a 1,1’-ferrocendiyl unit. This chain has been 
designed initially, following to calculations of the 
ring strain and configurational stability for a range of 
phosphoric acids of this class. Results of these 
calculations are reported hereafter in Scheme 1. 
Two factors have been initially identified as crucial 
for the choice of the tethering chain. First, the strain 
energy associated with the macrocyclic structure: the 
longer the tethering chain “X” is, the easier the 
cyclization process would be. Secondly, the 
configurational stability of the planar chiral scaffold: 
a long linker “X” might induce loss of the 
configurational stability, by allowing easy rotation of 
the phenylene rings of the paracyclophane moiety 
around the X-Caryl-O axis. The nature of the tethering 
chain must therefore be finely adjusted. DFT 
calculations have been run to estimate ring strain 
energies for paracyclophanic acids, relative to the 
BINOL-derived phosphoric acid (ERSE), according 
to the isodesmic reaction depicted in Scheme 1. The 
computed data, obtained at the M06/6-31G(d,p) level 
are shown. 
A 2-atoms chain (IIa) induces the larger ring strain 
energy, whereas 3-atoms (IId) and, to a larger extend, 
4-atoms chains (IIf) significantly reduce strain. The 
1,1’-ferrocendiyl unit (IIe) decreases significantly the 
ring strain with respect to the 3-atoms chains of 
IIb,c,d. This comparatively low ring strain likely 
relates to the high flexibility of the ferrocene unit, a 
unique structural feature that has allowed previously 
the synthesis of ferrocenophanes of various ring sizes, 
including the highly constraint phospha[1]- and 
phospha[2]ferrocenophanes.[15]  
 
  
ERSE (KJ/mol) 
 
 
Scheme 1. Isodesmic reaction used to compute the relative 
ring strain energy of IIa-f relative to the BINOL-derived 
phosphoric acid. 
Geometrical parameters of the macrocyclic 
structures IIa-f also correlate well with the computed 
ring strain energies:  smaller and less flexible linkers 
increase the deformation angles of the benzene ring 
of the paracyclophane unit (see sum of deformation 
angles, Ʃ+in Table3),[16] as well as the strain of the 
O-P-O bridge, as shown by the increased O…O 
distance (see Table 3 in the experimental section). 
Concerning the configurational stability of 
paracyclophanes, it has been computed recently that 
the barrier for rotation of the p-phenylene ring in 
[3.3] and [4.4]paracyclophanes are of about 300 and 
80 kJ.mol-1, respectively,[17] indicating that this 
barrier could be overcome only for the larger 
macrocycles and at high temperature. A similar trend 
is expected to be found in the targeted macrocyclic 
phosphoric acids. For the ferrocenic derivative IIe 
and the naphthalene derived macrocycle IIc, the 
energy barrier for the rotation of the p-phenylene 
units around the X-Caryl-O axis have been calculated 
at about 216 and 387 kJ.mol-1, respectively (at the 
M06/6-31G(d,p) level) in accordance with the chains 
size and flexibility of these structures.    
 
The theoretical studies above have oriented our 
choice toward 1,1’-ferrocendiyl units as the key 
components of phosphoric acids B, due to their low 
ring strain energy and high racemization barrier.  
Initial experiments have demonstrated that ferrocene-
based paracyclophanes of the general formula B can 
be accessed indeed and display acceptable chemical 
and configurational stability. As described in our 
previous communication, the ferrocene tethered 
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phosphoric acids 7 could be obtained according to 
two general strategies shown in Scheme 2.[11]  
 
 
 
Scheme 2. Synthetic approaches to the 1,1’-ferrocendiyl tethered paracyclophanes 7 
 
For both pathways, the key step is the 
macrocyclization reaction of a 1,1’-bis(p-
hydroxyphenyl)ferrocene, 3, with  bis(diisopropyl-
amino)cyanoethoxyphosphine 8a. The two pathways 
differ from each other by the reaction sequence 
leading to the ferrocenic diol 3. Pathway (a) involves 
the reaction of 1,1’-diiodoferrocene with a preformed 
biarylboronate in the presence of a palladium catalyst, 
under Suzuki conditions. Path (b) entails the 
synthesis of the bis-boronate 2 as a common platform 
allowing introduction of various aryl substituents 
(Ar) at a later step of the reaction sequence. The aryl 
substituents are introduced here by a palladium 
catalyzed Suzuki coupling on 2. In the final step of 
the reaction sequence, diols 3 have been reacted with 
bis(diisopropylamino)cyanoethoxyphosphine in the 
presence of four equivalents of tetrazole to afford the 
desired dl-phosphites 4.[18] Phosphites 4 have been 
oxidized into the corresponding phosphates with t-
butylhydroperoxide, then removal of the cyanoethyl 
chain by elimination of acrylonitrile under basic 
conditions (DBU) afforded the racemic acids 7. 
Pathway (a) has been applied to the synthesis of the 
phenyl-substituted phosphoric acid 7a (Ar = Ph), 
while path (b) allowed the synthesis of the m-
terphenyl substituted acid 7b.  
The racemic mixtures of 7a and 7b have been 
separated into enantiomerically pure acids by 
semipreparative HPLC on a CHIRALPAK® ID 
column. 
 
The use of semi-preparative chiral HPLC as the 
resolution method is a potential drawback of the 
synthetic approach above, as far as it might prevent 
suitable scale-up of the acids 7. On the other hand, 
the strategy of resolving the diol precursors 
commonly applied to the synthesis of chiral 
phosphoric acids,[19] can’t be applied here because of 
the peculiar structural features of this series.  Acids 7 
differ indeed from the BINOL- or SPINOL-derived 
analogues on that chirality is generated at the 
phosphination step, while the diol precursors are 
achiral. This means that resolution must be performed 
at a later step of the synthetic sequence.  
Thus, in order to avoid chiral HPLC separation, we 
have envisioned an original approach, i.e. the use of a 
chiral auxiliary as the phosphinating agent and 
subsequent separation of diastereomeric pairs. We 
have developed (S)-8b as a chiral variant of the 
classical cyanoethoxy-substituted phosphinating 
agent 8a. The new phosphorodiamidite (S)-8b 
contains a cyanoethoxy moiety as a precursor for the 
acidic P-OH function, but, unlike 8a, it displays a 
stereogenic carbon in close proximity to the 
phosphorus center. It is easily available in two steps, 
starting from the commercially available (R)-(-)-2-
chloro-1-phenylethanol, as shown in Scheme 3. After 
a Cl/CN substitution step, the resulting (S)-3-
hydroxy-3-phenylpropanenitrile[20] has been reacted 
with (iPr2N)2PCl at room temperature in the presence 
of Et3N. The desired phosphorodiamidite (S)-8b has 
been isolated as a white solid after filtration on a 
silica gel column. 
 
Scheme 3. Synthesis of the chiral phosphorodiamidite (S)-
8b. 
Phosphorodiamidite (S)-8b has been used as the 
phosphinating agent for the previously reported diols 
3a (Ar = Ph) and 3b (Ar = m-terphenyl), but also for 
the newly synthesized ferrocenic diols 3c,d (Ar = p-
biphenyl and 3,5-(CF3)2C6H3), as shown in Scheme 4. 
Diol 3c has been prepared via palladium catalyzed 
coupling of 1,1’-diiodoferrocene, 1, with the 
corresponding biaryl-boronate (path (a) in Scheme 2). 
Diol 3d has been obtained via path (b) in Scheme 2, 
i.e. coupling of 1-bromo-3,5-bis(trifluoromethyl)-
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benzene with the ferrocenic bis-boronate 2 (PG = 
methoxymethyl, catalyst = Pd(PPh3)4). The 
experimental procedures for these reactions are given 
as Supporting Information.  
 
Scheme 4. Use of the chiral phosphorodiamidite (S)-8b in 
the synthesis of phosphoric acids 7. 
 
Diols 3a-d have been reacted with the chiral 
phosphorodiamidite (S)-8b in the presence of 1H-
tetrazole to afford the desired macrocyclic, 
paracyclophane type phosphites 5a-d (Scheme 4). In 
principle, the cyclization step might afford both the 
meso and dl isomers of 5, but, gratifyingly, these 
reactions occurred with high stereoselectivity leading 
to the desired dl isomers as the only isolated products. 
We can assume that steric effects are responsible for 
the observed selectivity, as far as the steric hindrance 
of the Ar substituents is expected to favor their 
positioning on opposite faces of the paracyclophane 
ring. From these reactions, phosphites 5a-d have been 
isolated as mixtures of two epimers in 1:1 to 7:3 
ratios.  The mixtures have been oxidized with 
tBuOOH to obtain the corresponding phosphates 6a-
d. The four phosphates could be separated easily into 
pure diastereomers by either column chromatography 
(for 6b-d) or HPLC (for 6a). Thus, for instance, 
phosphates 6c,c’ (Ar = 4-biphenyl) have been 
separated by flash chromatography on silica gel 
(Combiflash) with a toluene/heptane/THF gradient 
(from 60:30:0 to 60:30:2) as the eluent.  6c: Rf = 0.39, 
[𝑎]
𝐷
20
= +1151 (c=0.5, CHCl3); 6c’: Rf =  0.34, [𝑎]𝐷
20
= -
1138 (c=0.5, CHCl3) (in toluene/heptane/THF = 
6:3:1).  
An X-ray crystal study on 6c’ demonstrated an (S)-
configuration of its planar chiral scaffold (Figure 2). 
Since 6c’ displays a negative rotatory power, we 
tentatively assume that, in the whole series, negative 
alpha-values are associated to phosphates and 
phosphoric acids with (S)-configurations. 
 
 The phosphates 6 are chemically and 
configurationally stable: neither decomposition nor 
interconversion of isomeric derivatives has been 
observed after either prolonged storage in air at room 
temperature or heating overnight at 80°C.  
 
Figure 2. X-Ray crystal structure of (-)-(SP,S)-6c’.  
The last step of the reaction sequence in Scheme 4 
is the removal of the chiral auxiliary. The 1-phenyl-2-
cyanoethyl chain could be removed under the 
conditions usually applied to removal of the 
analogous achiral cyanoethyl chain: DBU easily 
induces deprotonation and subsequent elimination of 
3-phenylacrylonitrile, with concomitant generation of 
the desired phosphoric acid salt. Starting from single 
epimers of phosphates 6, the enantiomerically 
enriched acids 7a-d have been obtained as yellow-
orange solids after filtration on silica gel with a 
DCM/MeOH gradient (0 to 10% MeOH) and workup 
with aqueous HCl (6N). The enantiomeric excesses 
of the acids have been measured by HPLC. 
Unlike the corresponding phosphates 6, acids 7 
displayed moderate thermal stability giving non-
identified decomposition products after heating at 
60°C in toluene for several hours. For instance, 7a 
undergoes an estimated 10% decomposition after 
heating for 18h at 60°C. Therefore, to ensure the 
integrity of their molecular scaffold, these acids are 
stored routinely at -20°C and used then in catalytic 
experiments at room temperature. 
 
In summary, we have demonstrated here that the 
use of the chiral phosphorodiamidite (S)-8b as the 
phosphinating agent provides an easier access to the 
phosphoric acids 7, the first family of planar chiral 
acids based on paracyclophane structures.  
 
With suitable synthetic methods in hand, we have 
started then a systematic investigation of the behavior 
of acids 7 as Brønsted acid catalysts.  
Our investigations have been focused on the 
transfer hydrogenation of 2-substituted quinolines 
with the Hantzsch ester as a benchmark reaction 
(Table 1).[21] We have compared the catalytic 
properties of the four acids 7a-d which display aryl 
groups with various steric bulk and long-arm effects. 
The shape and bulk of these aryl substituents are 
P
O
O
Fe
N
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expected to play a major role in enantioselective 
catalysis, as impressively demonstrated with the 
analogous BINOL-derived phosphoric acids.[22]  
At first, the behavior of 7a-d has been surveyed in 
the reduction of 2-phenylquinoline with the Hantzsch 
ester 9a (R = Et, entries 1-4).  All catalytic 
experiments have been run in toluene at a 0.05 mmol 
scale. Standard conditions involve toluene as the 
solvent, room temperature, 10 mol% of chiral catalyst.  
Table 1. Survey of phosphoric acids and Hantzsch esters 
for the H-transfer hydrogenation of 2-phenylquinoline 
 
 
 Catal.  Hantzsch ester             
                       R 
Time 
(h)[a] 
Ee %b) 
(config) 
1 (+)-7a  9a Et 2 27 (S)c) 
2 (+)-7b 9a Et 2 60 (S) 
3 (+)-7c 9a Et  2 55 (S)d) 
4 (+)-7d 9a Et 2 56 (S) 
5 (-)-7e 9a Et 2 26 (R)f) 
6 (-)-7b 9b Me 16 50 (R) 
7 (-)-7b 9c t-Bu 20e) 70 (R) 
8 (-)-7b 9d CH2Ph 3 74 (R) 
9 (+)-7b 9e CH2(4-MeO-C6H4) 2 85 (S) 
10 (-)-7b 9f CH2(4-BnO-C6H4) 2 87 (R)c) 
Reactions were run at a substrate concentration of 0.05 to 
0.01 M, depending on the solubility of the Hantzsch ester 
in toluene. a) Reaction times giving total conversion rates 
(NMR monitoring of the crude mixtures). b) Ee.s 
determined by HPLC on CHIRALPACK® IB (i-PrOH/ 
heptane 5:95). Configuration assigned from []D values.[23] 
c) The same conversion rate and ee were observed at a 
catalyst loading of 5 mol%. d) CH2Cl2 and THF were also 
used as solvents in this reaction, they afforded however 
lower reaction rates and enantioselectivity levels (ee = 
30%). e) 80% conversion rate. f) 5 mol% catalyst. 
 
_____________________________________ 
 
Acids 7a-d displayed excellent catalytic activity at 
room temperature, as they give total conversion in 
less than 2 hours. As anticipated, the nature of the 
aryl substituents of the acids strongly modulates the 
enantioselectivity levels, with enantiomeric excesses 
going from 26%, for Ar = phenyl, to 60% for the 
bulky, m-terphenyl substituted acid.  
In addition to catalysts 7a-d, we have tested also the 
9-phenanthryl substituted acid 7e[24] (entry 5) since 9-
phenanthryl-substituents are known to give the most 
efficient acid in the binaphthyl series.[21a] Acid 7e 
afforded however a very low enantiomeric excess. 
Generally speaking, the substituent effects do not 
follow the same trends in the binaphthyl-derived and 
paracyclophane type phosphoric acids. Such 
divergent substituent effects can be easily understood 
as far as the two series display totally different 
structural features and, especially, different 
arrangements of the aryl groups around the 
phosphorus functions. Comparative views of the 
molecular structures of the two phenyl-substituted 
acids obtained from DFT calculations are given in 
Figure 3 above. 
 
                   
     
 
 
Figure 3. DFT computed molecular structures of a 
BINOL-derived phosphoric acid and the corresponding 
paracyclophanic acid 7a. 
Most particularly, in 7a the eclipsed conformation of 
the ferrocene unit and the parallel arrangement of the 
p-phenylene groups cause a bent arrangement of the 
O-P-O function and subsequent loss of the C2 
symmetry of the molecule. Therefore, while in the 
C2-symmetric BINOL-derived acid the phenyl 
groups are distributed symmetrically on opposite 
sides of the phosphorus function, in 7a one of the 
phenyl substituents becomes closer to the phosphorus 
function and the second one is kept away 
considerably. Based on these significant structural 
differences, we can’t expect similar trends in the 
structure-activity relationships in the two series. This 
obviously prevents from making predictive 
hypotheses, but, on the other hand, the peculiar 
structural features of acids 7 might hopefully give 
complementary applications, with respect to BINOL-
derived acids and analogues. 
 
From the initial screening of chiral acids in Table 1, 
entries 1-5, we retained 7b (Ar = terphenyl) as the 
most promising catalyst for the H-transfer reduction 
of 10a and we investigated then the role of the 
dihydropyridine partner (entries 2, 6-10 in Table 1). 
According to recent theoretical studies on the 
reduction of imines with Hantzsch esters, the esters 
are assumed to give H-bonds with the catalyst in the 
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stereodetermining H-transfer step.[25] Consequently, 
the nature of the ester should have effects on the 
reaction outcome in terms of stereochemical control. 
Although so far literature shows that the Hantzsch 
ester plays a minor role in analogous reactions,[21f,26] 
in our study an extensive screening of esters has 
allowed a significant improvement of the 
enantioselectivity levels.  Several known and new 
Hantzsch esters (e.g. R = t-Bu, CH2Ph, CH2(4-
MeOC6H4), CH2(4-BnO-C6H4)) have been prepared 
from formaldehyde, ammonium acetate and the 
desired acetoacetate, following an usual procedure.[27] 
  As shown in Table 1, in the reduction of 2-
phenylquinoline catalyzed by acid 7b, the 
enantiomeric excess increased with the steric 
hindrance of the Hantzsch esters (R = Me<Et<tBu). 
Finally, benzyl esters afforded the highest 
enantioselectivity levels, with an 88% ee obtained 
with ester 9f, R = CH2(4-BnO-C6H4). In these 
reactions, the catalyst loading could be decreased to 5 
mol% without decreasing the conversion rate and 
enantioselectivity. 
 
With these improved conditions in hand (7b as the 
catalyst and 9f as the reducing agent) we have 
investigated the scope of the H-transfer reaction by 
varying the quinoline substrates. The main results are 
summarized in Table 2.  
Table 2. Survey of 2-substituted quinolines, 10, in H-
transfer reductions promoted by 7b. 
 
 
 Substrate 
          R’ 
Acid Product[a] Ee % [b] 
(config.) 
1 10a Ph (-)-7b 11a 87 (R) 
2 10b 4-MeO-C6H4 (+)-7b 11b 83 (S) 
3 10c 2-naphthyl (+)-7b 11c 92 (S) 
4 10d p-biphenyl (-)-7b 11d 82 (R) 
5 10e 3,5(CF3)2C6H3 (-)-7b 11e[c] 87 (+) 
6 10f 1-naphthyl (-)-7b 11f[c] 40 (R) 
7 10g C6H11 (-)-7b 11g[c] 40 (R)  
a) Conversion rates are quantitative. b) Configuration 
assigned from []D values of known compounds: 
11a,b,c,[23] 11d,[21a] 11f,[28] 11g.[29] c) conversion rate 50%.  
 
These experiments show that the new catalyst 7b 
affords high levels of enantioselectivity (ee 82-92%) 
in the reduction of various -aryl substituted 
quinolines (entries 1-5). Under the same conditions, 
alkyl substituted quinolines are reduced with lower 
conversion rates and enantiomeric excess (entry 7: R’ 
= cyclohexyl, 40% ee). Even so, the potential of 
planar chiral paracyclophanic acids as 
enantioselective organocatalyst is demonstrated here. 
 
Conclusion 
This work has disclosed phosphoric acids 7 as the 
first series of enantiomerically enriched phosphoric 
acids with paracyclophane structures. Their 
unprecedented scaffolds display an O-P-O chain and 
a 1,1’-ferrocenediyl units tethering the aromatic rings 
of the paracyclophane, while suitably positioned 
aromatic substituents generate planar chirality. We 
have demonstrated that the planar chiral phosphoric 
acids 7 display high catalytic activity and promising 
enantioselectivity levels in model H-transfer 
reductions (ee.s up to 92%). Their behavior as 
Brønsted acid organocatalysts will be further 
investigated. Given their peculiar structural features, 
including the lack of C2-symmetry, it can be 
anticipated that these acids will have complementary 
application fields with respect to other known chiral 
phosphoric acids. Further studies of their catalytic 
properties are ongoing in our group. 
Experimental Section 
Computational method 
Calculations have been carried out with the Gaussian09 
package of programs.[30]  Full geometry optimizations for 
all compounds were carried out with the use of the M06[31] 
density functional level of theory and the 6-31G(d,p) basis 
set for all atoms. This level of calculation is known to 
produce reasonable geometries and energies for molecules 
in which non-covalent interactions, like - interactions in 
paracyclophane-type systems, play a noticeable role. To 
get accurate geometries and energies, the SCF convergence 
criterion has been systematically tightened to 108 a.u., and 
the force minimizations were carried out until the rms 
force becomes smaller than (at least) 1 x 105 a.u. 
Frequency analyses were carried out to confirm that the 
reported structures are minima or transition states on the 
M06/6-31G(d,p) potential energy surface.  
Table 3. Computed relative ring strain energy and 
geometric parameters for IIa-f. 
 
 ERSEb Oc Cc Oc Cc Ʃ+ dO–Od 
IIa 87 11.1 10.0 2.6 11.8 35.5 2.611 
IIb 43 7.8 6.2 2.1 6.3 22.4 2.596 
IIc 40 9.5 8.2 2.5 0.9 21.1 2.601 
IId 35 7.5 6.7 2.2 5.7 22.1 2.596 
IIe 17 6.0 4.4 2.1 2.8 15.3 2.582 
IIf 13 4.2 3.0 2.3 4.7 14.2 2.573 
a Angle O (C) is defined by lines L1 and LO (LC). Angle O (C) 
is defined by line LO (LC) and the C1-O7 (C4-C8) bond. L1 goes 
through the midpoints of C2-C6 and C3-C5. LO (LC) goes through 
the midpoints of C2-C6 (C3-C5) and C1 (C4). a ring strain energy 
relative to the BINOL-derived phosphoric acid in kJ/mol. b 
phenylene ring deformation angles in degrees. c O…O distance in 
Å. dO-O = 2.536 Å for the BINOL-derived phosphoric acid.  
General. Semipreparative HPLC was carried out on a SiO2 
column (250 x 10 mm, 5 mic). 31P NMR have been 
recorded at 202 MHz. Phosphoric acid (-)-7e (Ar = 9-
phenanthryl) has been prepared according to Scheme 2b. 
 7 
Quinolines 10b-f[32] and 10g[33] have been prepared 
according to reported methods. 
Synthesis of (S)-(2-cyano-1-phenylethyl) N,N,N',N'-
tetra-isopropylphosphorodiamidite  (S)-8b.  (S)-2-
Cyano-1-phenylethanol[34] (3.90 g, 26.5 mmol) was 
dissolved in dry diethyl  ether (50 mL), treated with 
anhydrous triethylamine (4.06 mL, 29.2 mmol) and cooled 
to 0°C. A solution of bis(diisopropylamino)chloro-
phosphine (7.50 g, 26.5 mmol) in dry ether (30 mL) was 
added dropwise, the mixture was allowed to warm to room 
temperature and stirred overnight. The white solid was 
filtered off, the solution was evaporated under reduced 
pressure. The final product was purified by filtration on a 
short silica gel column with heptane/ethyl acetate/Et3N 
70:29:1 as the eluent to furnish (S)-8b as a white solid. 31P 
NMR (CDCl3): δ 114 ppm. 1H NMR (500 MHz, CDCl3) : 
7.41 (d, J = 7.8 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.31 (t, J 
= 7.8 Hz, 1H), 4.85 (dt, J = 11.4, 6 Hz, 1H), 3.6 (m, 2H), 
3.5 (m, 2H), 2.85 (ddd, J = 16.3, 6.2 Hz, 1H), 2.78 (dd, J = 
16.3, 5.0 Hz, 1H), 1.27 (d, J = 6.8 Hz, 6H), 1.19 (d, J = 6.8 
Hz, 6H), 1.14 (d, J = 6.8 Hz, 6H), 1.03 (d, J = 6.8 Hz, 6H).  
13C NMR (75.5 MHz, CDCl3): δ 141.1 (C), 128.5 (CH), 
128.3 (CH), 126.2 (CH), 117.3 (CN), 71.3 (d, J = 18.6 Hz, 
CH), 45.2 (d, J = 13.1 Hz, CH), 44.8 (d, J = 13.1 Hz, CH), 
28.6 (d, J = 4.4 Hz, CH2), 24.7 (CH3), 24.6 (CH3), 24.5 
(CH3), 24.4 (CH3), 24.3 (CH3) ppm.  HRMS (ESI) calcd. 
for C21H36N3OP [M+H2O+H]+: 396.2780, found: 396.2809.  
[𝑎]
𝐷
20
= +60 (c = 1, CHCl3). 
Representative procedures for the synthesis of the 
phosphoric acids 7:.Phosphoric acid 7a (Ar = Ph)  
(a) Phosphites 5a,a’. To a solution of 1,1’-bis-(4-hydroxy-
3-phenyl-1-phenyl)-ferrocene 3a[11] (261 mg, 0.50 mmol) 
and 1H-tetrazole (147 mg, 2.00 mmol, 4 eq.) in anhydrous 
DCM (25 mL) was added dropwise via cannula a solution 
of ((S)-2-cyanoethyl-1-phenyl)-N,N,N',N'-tetraisopropyl-
phosphorodiamidite (S)-8b (226 mg, 0.60 mmol, 1.2 eq.) in 
anhydrous DCM (5 mL). The flask was then equipped with 
a reflux condenser and the mixture was heated at 40 °C for 
3 h. The reaction was then quenched by addition of 
saturated aqueous NaHCO3 (20 mL) and extracted twice 
with DCM (2x20 mL). The organic phase was dried over 
MgSO4 and the solvents were removed under reduced 
pressure. Purification by flash chromatography on silica 
gel (eluent: heptane/EtOAc 9 : 1) gave the desired 
macrocyclic phosphites 5a,a’ (146 mg, 42% yield) in a 1:1 
ratio, as an orange solid. Rf = 0.6 (heptane/EtOAc 7:3). 31P 
NMR (CDCl3): δ 131.2 and 130.9 ppm.  1H NMR (500 
MHz, CDCl3) : δ 7.60-7.25 (m, 14H), 7.14-7.08 (m, 1H), 
6.92-6.80 (m, 2H), 6.61-6.53 (m, 1H), 6.44-6.15 (m, 3H), 
5.46-5.32 (m, 1H), 4.54 (bs, 1H), 4.50 (bs, 3H), 4.39 (bs, 
2H), 4.35 (bs, 2H), 2.81-2.60 (m, 2H). HRMS (ESI) calcd. 
for C43H32FeNO3P [M+H]+: 698.1547, found : 698.1486. 
(b) Phosphates 6a, 6a’.  A mixture of phosphites 5a,a’ 
(140 mg, 0.20 mmol) was dissolved in DCM (6 mL). 
TBHP (5.5M in decane, 110 L, 0.60 mmol) was added to 
the solution at 0 °C. Then the reaction mixture was 
allowed to warm to room temperature and stirred for 45 
minutes. The reaction was treated with saturated aqueous 
Na2S2O3. The layers were separated, the organic layer was 
dried over MgSO4 and concentrated in vacuo. The crude 
mixture was purified by chromatography on silica gel 
(heptane/EtOAc 7:3, Rf = 0.2) to afford a mixture of 6a,a’ 
(140 mg, 98% yield) as an orange solid. The mixture was 
separated by semi-preparative HPLC, with 
heptane./toluene/THF 35:70:5. Retention times: 6a, 21 
min; 6a’, 24 min. 
6a: 31P NMR (CDCl3) : δ -15 ppm.  1H NMR (500 MHz, 
CDCl3) : δ 7.54 (m, 2H), 7.5-7.4 (m, 7H), 7.40 (t, J = 7.3 
Hz, 1H), 7.3 (m, 3H), 7.14 (m, 2H), 6.98 (bs, 2H), 6.86 (d, 
J = 8.6 Hz, 1H), 6.34 (dd, J = 8.6, 2.3 Hz, 1H), 6.27 (dd, J 
= 8.3, 2.3 Hz, 1H), 6.17 (d, J = 8.3 Hz, 1H), 5.32 (dt, JH-P = 
6.9, J = 6.2 Hz, 1H), 4.62 (s, 1H), 4.59 (s, 1H), 4.53 (s, 
1H), 4.48 (s, 1H), 4.40 (s, 2H), 4.37 (s, 2H), 2.83 (d, J = 
6.2 Hz, 2H).  ]13C NMR (75 MHz, CDCl3) : δ 146.8 (d, J = 
6.4 Hz, C), 145.9 (d, J = 8.6 Hz, C), 137.2 (C), 136.5 (C), 
133.9 (C), 132.4 (d, J = 7.5 Hz, C), 131.3 (C), 130.5 (C), 
129.6 (CH), 129.2 (CH), 129.0 (CH), 128.9 (CH), 128.8 
(CH), 128.3 (CH), 128.1 (CH), 127.9 (CH), 127.2 (CH), 
126.2 (CH), 125.6 (CH), 122.4 (CH), 120.1 (CH), 115.5 
(CN), 85.8 (C), 76.6 (d, J = 6.6 Hz, CH), 69.9 (CH), 69.8 
(CH), 69.3 (CH), 66.6 (CH), 66.5 (CH), 65.6 (CH), 65.4 
(CH), 27.6 (d, J = 8.8 Hz, CH2). IR: νmax = 3031, 3057, 
2961, 2925, 1732, 1599, 1574, 1512, 1495, 1457, 1412, 
1303, 1261, 1211, 1055, 1036, 1022, 930.  HRMS (ESI) 
calcd. for C43H33FeNO4P [M+H]+: 714.1497, found: 
714.1487. [𝑎]
𝐷
20
 = +877 (c = 1, CHCl3). 
6a’:  31P NMR (CDCl3): δ -15 ppm.  1H NMR (300 MHz, 
CDCl3) : δ 7.6-7.3 (m, 13H), 7.3-7.2 (m, 3H), 6.99 (bs, 2H), 
6.62 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 8.5 Hz, 1H), 6.26 (dd, 
J = 8.5, 1.5 Hz, 1H), 6.22 (dd, J = 8.5, 1.7 Hz, 1H), 5.50 
(m, 1H), 4.61 (bs, 2H), 4.50 (bs, 2H), 4.40 (bs, 2H), 4.38 
(bs, 2H), 2.67 (dd, J = 16.5, 4.8 Hz, 1H), 2.46 (dd, J = 16.5, 
7.4 Hz, 1H).  13C NMR (75.5 MHz, CDCl3) : δ 146.6 (C), 
146.5 (C), 137.5 (C), 136.9 (C), 136.4 (C), 133.1 (C), 
132.6 (C), 131.1 (C), 130.8 (C), 129.8 (CH), 129.5 (CH), 
129.3 (CH), 129.0 (CH), 128.8 (CH), 128.0 (CH), 127.7 
(CH), 126.4 (CH), 125.9 (CH), 125.4 (CH), 122.0 (CH), 
120.5 (CH), 115.6 (CN), 85.8 (C), 76.2 (d, J = 5.4 Hz, CH), 
69.9 (CH), 69.3 (CH), 66.7 (CH), 66.6 (CH), 65.6 (CH), 
65.5 (CH), 26.7 (d, J = 6.5 Hz, CH2).  IR: νmax = 3056, 
3031, 2926, 2854, 1732, 1600, 1574, 1512, 1495, 1457, 
1412, 1294, 1262, 1211, 1129, 1037, 1014, 973, 936, 822.  
HRMS (ESI) calcd. for C43H33FeNO4P [M+H]+ : 714.1497, 
found : 714.1498.  [𝑎]
𝐷
20
 = -871 (c = 1, CHCl3). 
(c) Phosphoric acid (R)-7a.  Phosphate (R)-6a (45 mg, 
0.06 mmol) was dissolved in DCM (2 mL) and DBU (19 
L, 0.12 mmol) was added at rt. After 30 min, the mixture 
was purified by column chromatography with a 
DCM/MeOH gradient (100:0 to 90:10; Rf = 0.2). The 
crude 6a.DBU salt was diluted in DCM (10 mL) and 
treated with HCl 6N (3*10 mL). The layers were separated 
and the organic layer was concentrated in vacuo to afford 
the chiral phosphoric acid (R)-7a[11] (35mg, 95% yield). 
[𝑎]
𝐷
20
 = +931 (c = 1, CHCl3). The enantiomeric excess of 
the acids was measured by HPLC on an ID column. 
 
Phosphoric acid 7b (Ar = (5’-m-terphenyl) 
(a) Phosphites 5b,b’ were obtained from 3b,[11] in 39% 
yield, as a 6:4 mixture of isomers (Rf = 0.7 in heptane/ 
EtOAc 7:3). 31P NMR (CDCl3): δ 133 and 131 ppm. 
HRMS (ESI) calcd. for C67H49FeNO3P [M+H]+: 1002.2799, 
found : 1002.2784.  
(b) Phosphates 6b, 6b’ were separated on a CombiFlash® 
system using a silica gel column. Eluents: 
toluene/heptane/THF gradient from 65:35:0 to 65:35:1.5. 
Rf = 0.41 for 6b (major) and 0.38/ for 6b’ 
(toluene/heptane/THF = 6:3.5:1).  
6b:  31P NMR (CDCl3): δ -15 ppm. 1H NMR (300 MHz, 
CDCl3): δ 7.93 (bs, 1H), 7.8-7.6 (m, 13H), 7.6-7.3 (m, 
12H), 7.2-7.0 (m, 8H), 6.39 (d, J = 8.5 Hz, 1H), 6.33 (bs, 
2H), 5.35 (m, 1H), 4.63 (s, 1H), 4.60 (s, 1H), 4.54 (s, 1H), 
4.51 (s, 1H), 4.39 (s, 2H), 4.36 (s, 2H), 2.64 (dd, J = 16.0, 
6.0 Hz, 1H), 2.53 (dd, J = 16.0, 6.0 Hz, 1H).  13C NMR 
(75.5 MHz, CDCl3) : δ 147.0 (d, J = 6.9 Hz, C), 145.9 (d, J 
= 9.5 Hz, C), 142.5 (C), 142.1 (C), 141.4 (C), 140.7 (C), 
138.3 (C), 138.1 (C), 136.3 (C), 133.5 (C), 132.1 (d, J = 
6.5 Hz, C), 131.5 (C), 130.9 (C), 129.5 (CH), 129.3 (CH), 
129.0 (CH),128.9 (CH), 128.1 (CH), 128.0 (CH), 127.7 
(CH), 127.5 (CH), 127.4 (CH), 127.2 (CH), 127.1 (CH), 
126.2 (CH), 126.1 (CH), 125.9 (CH), 122.5 (CH), 120.5 
(CH), 115.3 (CN), 85.9 (C), 85.8 (C), 76.8 (CH), 70.0 
(CH), 69.3 (CH), 67.0 (CH), 66.8 (CH), 65.7 (CH), 65.5 
(CH), 27.2 (d, J(P-C) = 7.2 Hz, CH2).  IR : νmax = 3058, 2955, 
2924, 2854, 1716, 1684, 1595, 1512, 1498, 1455, 1414, 
1302, 1267, 1231, 1205, 1183, 1136, 1078, 1035, 934, 877.  
HRMS (ESI) calcd. for C67H49FeNO4P [M+H]+: 1018.2749, 
found : 1018.2766.  [𝑎]
𝐷
20
 = +918 (c = 1, CHCl3). 
6b’: 31P NMR (CDCl3): δ -15 ppm.  1H NMR (300 MHz, 
CDCl3) : δ 8.08 (bs, 1H), 7.9-7.7 (m, 13H), 7.7-7.4 (m, 
12H), 7.3-7.2 (m, 7H), 6.88 (d, J = 8.5 Hz, 1H), 6.46 (d, J 
= 8.5 Hz, 1H), 6.42 (d, J = 8.5 Hz, 1H), 6.34 (d, J = 8.5 Hz, 
1H), 5.69 (m, 1H), 4.73 (s, 1H), 4.71 (s, 1H), 4.61 (s, 1H), 
4.59 (s, 1H), 4.50 (s, 2H), 4.48 (s, 2H), 2.80 (dd, J = 16.5, 
4.7 Hz, 1H), 2.52 (dd, J = 16.5, 8.4 Hz, 1H). 13C NMR (75 
MHz, CDCl3) : δ 146.8 (d, J = 9.9 Hz, C), 146.6 (d, J = 9.7 
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Hz, C), 142.6 (C), 142.4 (C), 141.3 (C), 140.7 (C), 138.5 
(C), 137.8 (C), 136.0 (d, J = 4.8 Hz, C), 132.7 (d, J = 6.7 
Hz, C), 132.4 (d, J = 4.6 Hz, C), 131.5 (C), 131.0 (C), 
129.8 (CH), 129.4 (CH), 129.1 (CH), 128.2 (CH), 127.8 
(CH), 127.7 (CH), 127.5 (CH), 127.1 (CH), 126.5 (CH), 
126.2 (CH), 126.1 (CH), 125.7 (CH), 122.3 (CH), 120.4 
(CH), 115.2 (CN), 85.7 (C), 85.6 (C), 76.2 (d, J = 4.9 Hz, 
CH), 70.0 (CH), 69.4 (CH), 66.9 (CH), 66.7 (CH), 65.6 
(CH), 26.3 (d, J = 5.6 Hz, CH2).  IR: νmax = 3035, 2926, 
2855, 1595, 1513, 1456, 1414, 1297, 1232, 1206, 1036, 
1009, 966, 937, 877.HRMS (ESI) calcd. for C67H49FeNO4P 
[M+H]+ : 1018.2749, found : 1018.2745.  [𝑎]
𝐷
20
 = -710 (c = 
1, CHCl3).   
(c) Phosphoric acid (R)-7b was obtained in 67% yield (53 
mg) from (R)-6b (81 mg).  31P (DMSO-d6): δ -12. []D =   
+775 (c = 1, CH2Cl2). HPLC: ID column, 
THF/Heptane/TFA/Et3N 60:40:0.5:0.3). 
 
Phosphoric acid 7c (Ar = p-biphenyl). 
(a) Phosphites 5c,c’ were obtained from 3c[11]  in 44% 
yield, as a 1:1 mixture of isomers (Rf = 0.5 in heptane/ 
EtOAc 7:3). 31P NMR (CDCl3): δ 132 and 131 ppm. 
HRMS (ESI) calcd. for C55H40FeNO3P [M+H]+: 850.2173, 
found: 850.2178. The starting diol 3c has been prepared 
according to path (a) in Scheme 2 (see Supporting 
Information). 
(b) Phosphates 6c, 6c’ were separated on a CombiFlash® 
system using a silica gel column. Eluents: 
toluene/heptane/THF gradient from 60:30:0 to 60:30:2. Rf 
= 0.39 for 6c and 0.34 for 6c’ (toluene/heptane/THF = 
6:3:1). 6c: 31P NMR (CDCl3): δ -15 ppm.  1H NMR (500 
MHz, CDCl3) :  7.8-7.6 (m, 8H), 7.6-7.3 (m, 13H), 7.1 (m, 
2H), 7.04 (bs, 2H), 6.89 (d, J = 8.4 Hz, 1H), 6.34 (d, J = 
8.4 Hz, 1H), 6.27 (bs, 2H), 5.47 (m, 1H), 4.66 (bs, 2H), 
4.58 (bs, 1H), 4.54 (bs, 1H), 4.44 (bs, 2H), 4.42 (bs, 2H), 
2.87 (d, J = 5.9 Hz, 2H).  13C NMR (75 MHz, CDCl3): δ 
147.0 (d, J = 7.3 Hz, C), 146.2 (d, J = 10.5 Hz, C), 141.0 
(C), 140.9 (C), 140.7 (C), 140.6 (C), 136.6 (C), 136.3 (C), 
136.2 (C), 133.4 (C), 131.9 (d, J = 7.9 Hz, C), 132.0 (C), 
131.9 (C), 130.1 (CH), 129.7 (CH), 129.2 (CH), 129.0 
(CH), 128.9 (CH), 128.0 (CH), 127.9 (CH), 127.5 (CH), 
127.4 (CH), 126.2 (CH), 125.9 (CH), 122.3 (CH), 120.4 
(CH), 115.6 (CN), 86.5 (C), 86.4 (C), 76.7 (C), 70.1 (CH), 
69.5 (CH), 66.9 (CH), 66.7 (CH), 65.8 (CH), 65.7 (CH), 
27.6 (d, J = 7.3 Hz, CH2).  IR: νmax = 3032, 2967, 2926, 
2855, 1601, 1508, 1488, 1458, 1399, 1367, 1304, 1258, 
1212, 1185, 1128, 1055, 1034, 1022, 978, 934, 842, 768.  
HRMS (ESI) calcd. for C55H40FeNO4P [M+H]+: 866.2123, 
found: 866.2188.  [𝑎]
𝐷
20
 =  +1151 (c = 0.5, CHCl3).  
6c’: 31P NMR (CDCl3): δ -15 ppm.  1H NMR (500 MHz, 
CDCl3) : δ 7.8-7.6 (m, 9H), 7.6-7.3 (m, 11H), 7.2 (m, 2H), 
7.07 (bs, 2H), 6.68 (d, J = 8.0 Hz, 1H), 6.43 (d, J = 8.0 Hz, 
1H), 6.31 (dd, J = 8.0, 2.1 Hz, 1H), 6.27 (dd, J = 8.0, 2.1 
Hz, 1H), 5.56 (m, 1H), 4.67 (s, 2H), 4.55 (s, 2H), 4.45 (s, 
2H), 4.43 (s, 2H), 2.70 (dd, J = 16.5, 4.8 Hz, 1H ), 2.51 (dd, 
J = 16.5, 6.9 Hz, 1H). 13C NMR (75 MHz, CDCl3) : δ 
147.2 (d, J = 9.6 Hz, C), 147.0 (d, J = 10.3 Hz, C), 141.4 
(C), 141.3 (C), 141.2 (C), 140.9 (C), 136.9 (C), 136.3 (C), 
133.2 (d, J = 6.9 Hz, C), 132.7 (d, J = 6.0 Hz, C), 131.7 (C), 
131.4 (C), 130.4 (CH), 130.2 (CH), 130.1 (CH), 129.7 
(CH), 129.5 (CH), 129.4 (CH), 128.4 (CH), 128.1 (CH), 
128.0 (CH), 127.8 (CH), 127.7 (CH), 126.8 (CH), 126.4 
(CH), 126.0 (CH), 122.6 (CH), 120.9 (CH), 116.0 (CN), 
86.5 (C), 86.4 (C), 76.8 (d, J = 5.5 Hz, CH), 70.5 (CH), 
69.9 (CH), 67.2 (CH), 67.1 (CH), 66.1 (CH), 27.2 (d, J = 
7.7 Hz, CH2).  IR : νmax = 3030, 2925, 2853, 1730, 1600, 
1508, 1488, 1457, 1294, 1254, 1211, 1184, 1130, 1034, 
1007, 971, 934, 840, 820. HRMS (ESI) calcd. for 
C55H40FeNO4P [M+H]+: 866.2123, found: 866.2147.  
[𝑎]
𝐷
20
 =   -1138 (c = 0.5, CHCl3). An S-planar configuration 
has been assigned to compound 6c’ by X-ray diffraction 
studies: CCDC 951975 contains the corresponding 
crystallographic data. 
(c) Phosphoric acid (R)-7c was obtained in 33% yield (7 
mg) from (R)-6c (25 mg). 31P NMR (DMSO-d6): δ -12 
ppm.  1H NMR (600 MHz DMSO-d6): 7.78 (d, J = 8.0 Hz, 
4H), 7.77 (d, J = 7.3 Hz, 4H), 7.69 (d, J = 8.0 Hz, 4H), 
7.51 (t, J = 7.3 Hz, 4H), 7.40 (t, J = 7.3 Hz, 2H), 7.09 (bs, 
2H), 6.62 (d, J = 8.5 Hz, 2H), 6.50 (d, J = 8.5 Hz, 2H), 
4.86 (s, 2H), 4.74 (s, 2H), 4.45 (s, 2H), 4.41 (s, 2H).  13C 
NMR (150.7 MHz, DMSO-d6): δ 146.8 (d, J(P-C) = 5.6 Hz, 
C), 139.9 (C), 138.7 (C), 137.0 (C), 131.6 (d, J(P-C) = 5.2 
Hz, C), 129.8 (CH), 129.5 (C), 129.0 (CH), 127.5 (CH), 
127.1 (CH), 126.7 (CH), 126.5 (CH), 126.0 (CH), 121.2 
(CH), 86.0 (C), 69.3 (CH), 68.7 (CH), 66.6 (CH), 65.5 
(CH).  IR: νmax = 3029, 2923, 2852, 1600, 1507, 1488, 
1457, 1398, 1379, 1259, 1216, 1190, 1089, 1017, 1007, 
911, 838.  HRMS (ESI) calcd. for C46H33FeO4P: 736.1466, 
found : 736.1485.  [𝑎]
𝐷
20
 =   +966 (c = 0.7, CHCl3).   
Phosphoric acid 7d (Ar = 3,5-bis(trifluoromethyl)-
phenyl). 
(a) Phosphites 5d,d’ were obtained from 3d[11]  in 20% 
yield, as a 7:3 mixture of isomers (Rf = 0.7 in heptane/ 
EtOAc 7:3). 31P NMR (CDCl3): δ 136 and 133 ppm. 
HRMS (ESI) calcd. for C47H28F12FeNO3P [M+H]+: 
970.1043, found: 970.1098. The starting diol 3d has been 
prepared according to path (b) in Scheme 2 (see 
Supporting Information). 
(b) Phosphates 6d, 6d’ were separated on a CombiFlash® 
system using a silica gel column. Eluents: 
toluene/heptane/THF gradient from 70:30:0 to 70:30:1. Rf 
= 0.38 for 6d (major) and 0.34 for 6d’ 
(toluene/heptane/THF = 7:3:1).  
6d:  31P NMR (CDCl3): δ -12 ppm.  19F NMR (282.4 MHz, 
CDCl3): -62.5 and -62.6.  1H NMR (500 MHz, CDCl3): δ 
8.02 (s, 1H), 7.98 (s, 3H), 7.96 (s, 2H), 7.41 (m, 3H), 7.24 
(m, 2H), 7.01 (bs, 2H), 6.94 (d, J = 8.7 Hz, 1H), 6.46 (d, J 
= 8.7 Hz, 1H), 6.35 (d, J = 8.5 Hz, 1H), 6.23 (d, J = 8.53 
Hz, 1H), 5.56 (q, J = 6.5 Hz, 1H), 4.67 (s, 1H), 4.66 (s, 
1H), 4.64 (s, 1H), 4.57 (s, 1H), 4.51 (s, 2H), 4.47 (s, 1H), 
2.96 (d, J = 6.0 Hz, 2H). 13C NMR (75.5 MHz, CDCl3): δ 
146.6 (d, J(P-C) = 5.6 Hz, C), 145.2 (d, J(P-C) = 8.7 Hz, C), 
139.4 (C), 138.8 (C), 136.1 (C), 136.0 (C), 132.3 (q, J(F-C) 
= 33.9 Hz, C), 132.7 (C), 132.0 (q, J(F-C) = 33.6 Hz, C), 
131.6 (C), 131.2 (C), 129.9 (CH), 129.3 (CH), 129.2 (CH), 
127.5 (CH), 127.3 (CH), 127.2 (CH), 127.0 (CH), 125.7 
(CH), 123.6 (q, J(F-C) = 273.0 Hz, CF3), 123.5 (q, J(F-C) = 
273.0 Hz, CF3), 123.3 (CH), 121.8 (CH), 120.0 (CH), 
115.1 (CN), 85.3 (C), 85.2 (C), 77.0 (d, J(P-C) = 3.9 Hz, C), 
70.4 (CH), 69.7 (CH), 67.4 (CH), 67.1 (CH), 65.7 (CH), 
65.5 (CH), 27.5 (d, J(P-C) = 7.7 Hz, CH2).  IR : νmax = 3089, 
2929, 1723, 1621, 1604, 1514, 1457, 1414, 1373, 1277, 
1179, 1130, 1052, 1037, 1016, 931, 900.  HRMS (ESI) 
calcd. for C47H28F12FeNO4P [M+H]+ : 986.0992, found : 
986.1035.  [𝑎]
𝐷
20
 = +722 (c = 1, CHCl3).   
6d’:  31P NMR (CDCl3): δ -12.2 ppm.  19F NMR (282.4 
MHz, CDCl3): -62.57 and -62.53 ppm.  1H NMR (300 
MHz, CDCl3): δ 8.01 (s, 2H), 7.98 (s, 1H), 7.88 (s, 1H), 
7.80 (s, 2H), 7.43-7.38 (m, 3H), 7.35-7.30 (m, 2H), 7.02 (s, 
1H), 6.96 (s, 1H), 6.86 (d, J = 8.7 Hz, 1H), 6.43 (d, J = 8.7 
Hz, 1H), 6.29 (d, J = 8.8 Hz, 1H), 6.21 (d, J = 8.8 Hz, 1H), 
5.67 (q, J = 6.6 Hz, 1H), 4.65 (s, 1H), 4.61 (s, 2H), 4.52 (s, 
1H), 4.47 (s, 2H), 4.44 (s, 2H), 2.94 (dd, J = 16.7, 6.2 Hz, 
1H), 2.84 (dd, J = 16.7, 6.2 Hz, 1H).  13C NMR (75.5 MHz, 
CDCl3): δ 146.6 (d, J(P-C) = 5.6 Hz, C), 145.4 (d, J(P-C) = 8.7 
Hz, C), 139.3 (C), 138.8 (C), 136.1 (C), 136.0 (C), 132.7 
(C), 132.3 (q, J(F-C) = 33.3 Hz, C), 132.0 (q, J(F-C) = 33.3 Hz, 
C), 131.7 (C), 131.2 (C), 131.1 (C), 130.1 (CH), 129.4 
(CH), 129.3 (CH), 129.2 (CH), 129.1 (CH), 127.7 (CH), 
127.2 (CH), 127.0 (CH), 126.1 (CH), 125.3 (C), 123.1 
(CH), 121.8 (CH), 121.7 (CH), 120.2 (CH), 115.1 (CN), 
85.3 (C), 85.2 (C), 76.7 (d, J(P-C) = 3.3 Hz, C), 70.5 (CH), 
70.4 (CH), 69.8 (CH), 67.3 (CH), 67.1 (CH), 65.7 (CH), 
65.6 (CH), 27.0 (d, J(P-C) = 6.3 Hz, CH2).  IR : νmax = 3089, 
2931, 1719, 1620, 1604, 1514, 1457, 1413, 1373, 1277, 
1180, 1130, 1051, 1037, 1015, 934, 900.  [𝑎]
𝐷
20
 = -737 (c = 
1, CHCl3). 
 
General procedure for the synthesis of the Hantzsch 
esters 9d-f.[27] Paraformaldehyde (1 eq.), ammonium 
acetate (2 eq.), and the desired acetoacetate 
MeCOCH2CO2R (2 eq.) were refluxed under argon for 2 h 
under strong agitation. After cooling, the product was 
recrystallized from ethanol. 9d is a known product.[27]  
Bis-(4-methoxybenzyl) 2,6-dimethyl-1,4-dihydropyri-
dine-3,5-dicarboxylate, 9e: 1H NMR (500 MHz, DMSO-
 9 
d6) : δ 8.37 (bs, 1H), 7.27 (d, J = 8.5 Hz, 4H), 6.90 (d, J = 
8.5 Hz, 4H), 5.01 (s, 4H), 3.75 (s, 6H), 3.16 (s, 2H), 2.11 (s, 
6H). 
Bis-(4-benzyloxybenzyl) 2,6-dimethyl-1,4-dihydropyri-
dine-3,5-dicarboxylate, 9f: 1H NMR (300 MHz, DMSO-
d6): δ 8.38 (bs, 1H), 7.44-7.29 (m, 14H), 6.98 (d, J =8.4 Hz, 
4H), 5.09 (s, 4H), 5.01 (s, 4H), 3.75 (s, 6H),  3.16 (s, 2H), 
2.11 (s, 6H); 13C NMR (75 MHz, DMSO-d6): δ 166.9 (CO), 
158.0 (C), 147.0 (C), 137.0 (C), 129.4 (CH), 129.1 (C), 
128.4 (CH), 127.8 (CH), 127.6 (CH) 114.6 (CH), 96.9 (C), 
69.2 (CH2 ), 64.4 (CH2), 24.7 (CH2), 18.0 (CH3). HRMS 
(ESI) calcd. for C37H36NO6 [M+H]+: 590.2543, found: 
590.2524. 
Representative procedure for the catalytic reductions 
of -arylquinolines. 
A solution of 2-phenylquinoline 10a (11 mg, 0.05 mmol), 
Hantzsch dihydropyridine 9a (0.12 mmol) and the acid 
catalyst 7a (0.005 mmol) in toluene (1 ml) was stirred at r.t. 
for 2h. The solvent was removed under reduced pressure 
and the residue was purified on silica gel with toluene as 
the eluent. 2-Phenyl-1,2,3,4-tetrahydroquinoline 11a was 
obtained as a colorless oil. E.e.s were determined by HPLC 
using a CHIRALPAK® IB column. Eluent: i-PrOH/n-
heptane 5:95, at a flow rate of 1 mL/min [detection at 275 
nm]. Retention times:  6.7 min for (-)-(S)-11a and 8.2 min 
(+)-(R)-11a. [Litt:[23] (S)-11a: [𝑎]
𝐷
20
 = -35.7 (c = 0.8, 
CHCl3)]. 
2-(4-methoxyphenyl)-1,2,3,4-tetrahydroquinoline 11b: 
CHIRALPAK® IB. Eluent: i-PrOH/n-heptane, 5:95 at a 
flow rate of 1 mL/min [detection at 250 nm]. Retention 
times: 7.7 min [(-)-(S)-11b] and 17.9 min [(+)-(R)-11b]. 
[Litt:[23] (S)-11b: [𝑎]
𝐷
20
 = -26.1 (c = 1, CHCl3), 86% ee]. 
2-(2-naphthyl)-1,2,3,4-tetrahydroquinoline 11c: 
CHIRALPAK® IB. Eluent: i-PrOH/n-heptane, 5:95 at a 
flow rate of 1 mL/min [detection at 250 nm]. Retention 
times: 9.6 min [(-)-(S)-11c] and 15.5 min [(+)-(R)-11c]. 
[Litt:[23] (S)-11c: [𝑎]
𝐷
20
 = -27.5 (c = 1, CHCl3), 91% ee]. 
2-(p-biphenyl)-1,2,3,4-tetrahydroquinoline 11d: 
CHIRALPAK® IB. Eluent: i-PrOH/n-heptane, 5:95 at a 
flow rate of 1 mL/min [detection at 250 nm]. Retention 
times: 9.4 min [(-)-(S)-11d] and 17.9 min [(+)-(R)-11d]. 
[Litt:[21a] (S)-11d: [𝑎]
𝐷
20
 = -13.8 (c = 1, CHCl3), >99% ee]. 
2-(3,5-bis(trifluoromethyl)phenyl)-1,2,3,4-tetrahydro-
quinoline 11e: CHIRALPAK® IB. Eluent: i-PrOH/n-
heptane, 5:95 at a flow rate of 1 mL/min [detection at 250 
nm]. Retention times: 8.4 min [(-)-11e] and 17.2 min [(+)-
11e].  
2-(1-naphthyl)-1,2,3,4-tetrahydroquinoline 11f: 
CHIRALPAK® IB. Eluent: i-PrOH/n-heptane, 5:95 at a 
flow rate of 1 mL/min [detection at 250 nm]. Retention 
times: 10.7 min [(-)-(S)-11f] and 18.1 min [(+)-(R)-11f]. 
[Litt:[28] (R)-11c: [𝑎]
𝐷
20
= +117 (c = 1, CHCl3), 88% ee]. 
2-(1-cyclohexyl)-1,2,3,4-tetrahydroquinoline 11g:[21b] 
CHIRALPAK® IC. Eluent: i-PrOH/n-heptane, 2:98 at a 
flow rate of 1 mL/min [detection at 250 nm]. Retention 
times: 4.4 min [(+)-(S)-11g] and 4.7 min [(-)-(R)-11g]. 
[Litt:[29] (S)-11g: [𝑎]
𝐷
20
= +48.3 (c = 0.1, CHCl3), 96% ee]. 
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